▶ 調査レポート


• 英文タイトル:Polycystic Ovarian Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021- 2026)

Mordor Intelligenceが調査・発行した産業分析レポートです。多嚢胞性卵巣症候群治療の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測 / Polycystic Ovarian Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021- 2026) / MRC2103C130資料のイメージです。• レポートコード:MRC2103C130
• 出版社/出版日:Mordor Intelligence / 2021年2月27日
• レポート形態:英文、PDF、120ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥467,500 (USD4,250)▷ お問い合わせ
  Team User¥522,500 (USD4,750)▷ お問い合わせ
  Corporate License¥825,000 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)

The Polycystic Ovarian Syndrome (PCOS) Treatment Market is expected to register a growth rate of 5.2%, over the forecast period.

Owing to the current pandemic situation, various gynecological procedures and nonessential treatment have been postponed, also non-COVID-19 related research is being postponed by various companies which are leading to delayed product launches. Some disruptions in sourcing raw materials from impacted countries, such as China, were also observed in early 2020, but such disruptions are unlikely to have a significant impact on going forward. However, as earlier restrictions are now easing in a number of countries the market growth will also resume. ​

Polycystic ovary syndrome (PCOS) is a common hormonal endocrine disorder that affects women of childbearing age (15 to 49 years). According to the Centers for Disease Control & Prevention (CDC), polycystic ovary syndrome (PCOS) is the most common cause of female infertility. Also, as per a study published in September 2019, the prevalence of polycystic ovarian syndrome in adolescents based on the Rotterdam criteria was found to be 11.04%, based on the National Institute of Health criteria, it was 3.39%, and based on Androgen Excess and Polycystic Ovary Syndrome Society, it was 8.03%, worldwide. The increasing burden of PCOS and no targeted therapy for PCOS being available in the market creates a need to develop therapies to treat them. The players in the market are currently focusing on the unmet need of the market and strengthening their pipelines in order to leverage the opportunities, the commercialization of these robust pipeline is expected to propel market growth.For instance, Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, currently has the molecule HSD17B5 inhibitor in its pipeline, an enzyme that is overexpressed in adipose tissue of PCOS patients. Such developments are expected to boost the market over the forecast period.

Also, there has been several initiatives by the private and government firm in order to increase the awareness about the disease which is also expected to drive the market. For instance, in June 2020, National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Institute of Diabetes and Digestive and Kidney Diseases funded a study on ‘Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis’ and reported that polycystic ovary syndrome may have at least two different subtypes.

However, the side effects of symptomatic treatment drugs and lack of approved drugs directly targeting PCOS disease drugs act as among the major restraints to the PCOS treatment market.

Key Market Trends

Laparoscopic Ovarian Drilling is Expected to Hold Major Share Under Surgeries Over the Forecast Period

Laparoscopic Ovarian Drilling is among the most common surgeries performed by doctors in critical conditions. Since the fertility problems faced by the women are quite predominant because of this condition, and response to medications weakens over time, the surgery performed via a thin microscope though the abdomen is majorly preferred across the geography. As per the study published in 2019 by the Department of Gynecology and Obstetrics in major hospitals in France, after laparoscopic drilling, 47.4% (137 patients) had a pregnancy and 51.8% (71 patients) of these were spontaneous, also 16.6% (48 patients) women had at least two pregnancies after drilling and 56.3% (27 patients) of these were spontaneous. The study suggested that there is a high success rate in laparoscopic drilling in women, and that’s why it is most preferred. In addition, the cost-effective procedures drive the patients towards this surgical procedure for easy treatment of the disease. Thus, it is estimated to have a major share, over the forecast period.

However, the COVID-19 pandemic has had ramifications for ways of working, of various surgical procedures including laparoscopic ovarian drilling. In May 2020, University of Birmingham Experts at the University of Birmingham-led NIHR Global Research Health Unit on Global Surgery, published their findings that the patients undergoing surgery after contracting coronavirus are at increased risk of postoperative death and recommended to avoid all non-emergent surgeries. But, later the regulatory bodies in order to keep the normal surgical procedures going on imposed few guidelines specific to each specialty that has to be implemented and followed, for the surgeons to be able to continue to provide safe and effective care to their patients during the COVID-19 pandemic. These issued guidelines has allowed the healthcare providers to resume there surgery practices. And thus it is expected that in future to come the laparoscopic ovarian drilling procedures are also expected to resume to their normal growth.

North America is Estimated to Have Largest Share in the Global Market

Obesity which is considered as one of the major risk factors for PCOS has seen an upsurge increase during the pandemic. In September 2020, The Centers for Disease Control and Prevention (CDC) notified that adult obesity prevalence is increasing and racial and ethnic disparities persist owing to the current circumstances of work from home, less physical activities, financial and other stress among the adult population. The CDC stated that obesity remains high, and currently, twelve states have an adult obesity prevalence at or above 35 % including Alabama, Arkansas, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia. The data by CDC revealed that there is a high prevalence of obesity in North American countries which is going to increase the risk of PCOS and is anticipated to offer positive growth to the market.

The United States and Canada are highly advanced in terms of new technology procurement, early release of drugs in the market, this region has the presence of a major player base and also the strong product in the pipeline to propel market growth. For instance, AbbVie, a United States headquartered company currently has Elagolix (ABT-620), an oral gonadotropin-releasing hormone antagonist that is being studied for the treatment of endometriosis and PCOS. Also, in November 2019, the University of Illinois at Chicago funded clinical research to study the effect of salsalate administration on the ovarian capacity to secrete androgen and on insulin sensitivity in PCOS. The need to ease the treatment and procedures has evolved significantly in the past one decade which is the major reason giving rise to several R&D investments and venture partners funding for pharmaceutical companies in this region, and thus driving the market growth

Competitive Landscape

The major market players are focusing on symptomatic treatments and several have their drugs in clinical trials, but not approved for marketing. There is a growing focus on surgeries, for which many medical devices are inclined towards. Some of the major players in the market are Bayer AG, Ferring BV, Merck KGaA, Novartis, Pfizer, and Takeda, Teva Pharmaceutical Industries Limited, among others.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support


1.1 Study Assumptions and Market Definition
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Burden of PCOS
4.2.2 Growth in Initiatives by Government and Private Players to Raise Awareness
4.3 Market Restraints
4.3.1 Adverse Effects Associated with Treatment
4.3.2 Lack of FDA Approved Drugs Specific to Polycystic Ovarian Syndrome (PCOS)
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Treatment
5.1.1 Drug Class Contraceptives Insulin-sensitizing Agent Antidepressants Anti-obesity Others
5.1.2 Surgery Ovarian Wedge Resection Laparoscopic Ovarian Drilling Other Surgeries
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe France Germany United Kingdom Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 AbbVie Plc
6.1.3 Addex Therapeutics Ltd.
6.1.4 AstraZeneca PLC
6.1.5 Bayer AG
6.1.6 BIOCAD
6.1.7 Bristol-Myer Squibb Company
6.1.8 Crinetics Pharmaceuticals
6.1.9 EffRx, Inc.
6.1.10 Ferring BV
6.1.11 Johnson and Johnson
6.1.12 Merck KGaA